Find the Zheng Laboratory’s latest announcements, news, and media coverage here.
Recent Lab Announcements
- MAY 2022 | Best of luck to our postdoctoral fellow Pratik who has accepted a new position at Bristol Myers Squibb! We will miss you and all of your contributions to our work!
- MAY 2022 | Welcome to our new postdoctoral fellow Saikat Das! We look forward to your contributions!
- APRIL 2022 | Congratulations to Matt and Alexis on the publication of their review article “Overcoming Cancer Drug Resistance Utilizing PROTAC Technology” in Frontiers in Cell and Developmental Biology!
- APRIL 2022 | Welcome to our new postdoctoral fellow Hui Li! We look forward to working with you!
- SEPTEMBER 2021 | Congratulations to our lab post-doctoral fellow Pratik Pal, PhD, for the publication of his manuscript “Discovery of a Novel BCL-XL PROTAC Degrader with Enhanced BCL-2 Inhibition” in the Journal of Medicinal Chemistry.
- JUNE 2021 | Our Principle Investigator, Dr. Guangrong Zheng, has been awarded tenure at the University of Florida College of Pharmacy.
- APRIL 2021 | Pratik Pal, PhD, has won the Best Oral Presentation Award in the postdoctoral category at the 4th UF Drug Discovery Symposium hosted by the UF College of Pharmacy’s Center for Natural Products, Drug Discovery and Development (CNPD3). The title of his presentation is “Discovery of a BCL-XL/BCL-2 dual function PROTAC.” Congratulations!
- APRIL 2021 | Zhixing Wu, PhD, has joined the Zheng Lab as an Research Assistant Professor. Welcome!
An anticancer drug developed by researchers from the University of Florida College of Pharmacy has become the first drug of its kind allowed to proceed to clinical trial by the U.S. Food and Drug Administration. The drug, DT2216, targets leukemia, lymphoma, and breast and lung cancers. The researchers expect it will available for patients, in a clinical trial setting, in April or May this year.
University of Florida Health Cancer Center researchers have found a potential new way of targeting this population of immune-suppressive T cells that could possibly benefit a large population of cancer patients, including those who will not respond to other immunotherapies. The researchers discovered that B-cell lymphoma extra-large, or BCL-XL, is a potential molecular target of TI-Tregs, which play an important role within tumors to promote an immunosuppressive microenvironment and inhibit anti-cancer immunity.
It is interesting to compare today’s open access paper on converting the senolytic drug navitoclax into a PROTAC with recent efforts to improve navitoclax by conjugation with galactose. In both cases the objective is to reduce side-effects, but the strategies are quite different.
Researchers have developed a way to modify an existing cancer drug with toxic side effects into something that is less toxic to blood platelets and more effective at removing harmful and inflammatory senescent cells, one of the reasons we age, from mice.